Sun Faces Higher Cost In Challenge Of Wyeth’s $960 Million Patent Claim
This article was originally published in PharmAsia News
Sun Pharma could opt for an out-of-court settlement of U.S.-based Wyeth’s claim of $960 million in damages rather than face a court case that could end up costing the Indian drug maker even more if carried to the end.
You may also be interested in...
A new report focused on the European market says that winning trust is the key to taking AI adoption to the next stage. That approach was praised by MedTech Europe CEO Serge Bernasconi.
As the transition period following the UK’s withdrawal from the European Union draws to a close, cosmetics industry stakeholders are following final trade negotiations while readying themselves for new regulatory complexities.
Purdue’s opioid settlement is making headlines for the size of the financial penalty. But the plan to re-imagine Purdue as a ‘public benefit company’ could have far-reaching significance for the industry – if it ever gets off the ground.